(TOP (S (NP (NP (NNS Earnings)) (PP (IN for) (NP (NP (JJS most)) (PP (IN of) (NP (NP (DT the) (NN nation) (POS 's)) (JJ major) (JJ pharmaceutical) (NNS makers)))))) (VP (AUX are) (VP (VBN believed) (S (VP (TO to) (VP (AUX have) (VP (VBN moved) (ADVP (RB ahead)) (ADVP (RB briskly)) (PP (IN in) (NP (DT the) (date (JJ third) (NN quarter)))) (, ,) (SBAR (IN as) (S (NP (NP (NNS companies)) (PP (IN with) (NP (JJR newer) (, ,) (JJ big-selling) (NN prescription) (NNS drugs)))) (VP (VBD fared) (ADVP (RB especially) (RB well))))))))))) (. .)) )
(TOP (S (PP (IN For) (NP (DT the) (JJ third) (JJ consecutive) (NN quarter))) (, ,) (ADVP (RB however)) (, ,) (NP (NP (JJS most)) (PP (IN of) (NP (NP (DT the) (NNS companies) (POS ')) (NNS revenues)))) (VP (AUX were) (VP (VBN battered) (PP (IN by) (NP (JJ adverse) (NN foreign-currency) (NNS translations))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT the) (JJ strong) (NN dollar)) (ADVP (RB abroad)))))))) (. .)) )
(TOP (S (NP (NNS Analysts)) (VP (VBD said) (SBAR (IN that) (S (NP (NP (organization (NNP Merck)) (CC &) (NNP Co.)) (, ,) (NP (organization (NNP Eli) (NNP Lilly) (CC &) (NNP Co.))) (, ,) (NP (NNP Warner-Lambert) (NNP Co.)) (CC and) (NP (NP (DT the) (organization (NNP Squibb) (NNP Corp.)) (NN unit)) (PP (IN of) (NP (organization (NNP Bristol-Myers) (NNP Squibb)) (NNP Co.))))) (DT all) (VP (VBD benefited) (PP (IN from) (NP (NP (JJ strong) (NNS sales)) (PP (IN of) (NP (NP (RB relatively) (JJ new) (, ,) (JJ higher-priced) (NNS medicines)) (SBAR (WHNP (WDT that)) (S (VP (VBP provide) (NP (JJ wide) (NN profit) (NNS margins))))))))))))) (. .)) )
(TOP (S (NP (NP (RBR Less) (JJ robust) (NNS earnings)) (PP (IN at) (NP (NP (organization (NNP Pfizer) (NNP Inc.))) (CC and) (NP (organization (NNP Upjohn) (NNP Co.)))))) (VP (AUX were) (VP (VBN attributed) (PP (TO to) (NP (NP (NP (DT those) (NNS companies) (POS ')) (JJR older) (NNS products)) (, ,) (SBAR (WHNP (DT many) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBP face) (NP (NP (VBG stiffening) (NN competition)) (PP (IN from) (NP (NP (JJ generic) (NNS drugs)) (CC and) (NP (JJ other) (NNS medicines)))))))))))) (. .)) )
(TOP (S (NP (NP (person (NNP Joseph) (NNP Riccardo))) (, ,) (NP (NP (DT an) (NN analyst)) (PP (IN with) (NP (organization (NNP Bear) (, ,) (NNP Stearns) (CC &) (NNP Co.))))) (, ,)) (VP (VBD said) (SBAR (IN that) (S (PP (IN over) (NP (DT the) (JJ past) (JJ few) (NNS years))) (NP (JJS most) (NN drug) (NNS makers)) (VP (AUX have) (VP (VP (VBN shed) (NP (PRP$ their) (JJ slow-growing) (NNS businesses))) (CC and) (VP (VBN instituted) (NP (NP (JJ other) (NN cost) (NNS savings)) (, ,) (PP (JJ such) (IN as) (S (VP (VBG consolidating) (NP (NP (NN manufacturing) (NNS plants)) (CC and) (NP (JJ administrative) (NNS staffs))))))))))))) (. .)) )
(TOP (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (`` `) (S (`` `) (NP (JJ major) (JJ new) (NNS products)) (VP (AUX are) (VP (AUXG having) (NP (JJ significant) (NN impact)) (, ,) (PP (ADVP (RB even)) (IN on) (NP (NP (DT a) (NN company)) (PP (IN with) (NP (ADJP (RB very) (JJ large)) (NNS revenues))))))) (, ,) ('' ')) ('' ') (NP (NNP Mr.) (NNP Riccardo)) (VP (VBD said)) (. .)) )
(TOP (S (NP (NNS Analysts)) (VP (VBD said) (SBAR (S (NP (NP (NN profit)) (PP (IN for) (NP (NP (DT the) (NN dozen)) (CC or) (NP (ADJP (RB so) (JJ big)) (NN drug) (NNS makers))))) (, ,) (PP (IN as) (NP (DT a) (NN group))) (, ,) (VP (AUX is) (VP (VBN estimated) (S (VP (TO to) (VP (AUX have) (VP (VBN climbed) (NP (QP (IN between) (CD 11) (NN %) (CC and) (percentage (CD 14) (NN %))))))))))))) (. .)) )
(TOP (S (SBAR (IN While) (S (NP (DT that)) (VP (AUX 's) (RB not) (ADJP (JJ spectacular))))) (, ,) (NP (NP (person (NNP Neil) (NNP Sweig))) (, ,) (NP (NP (DT an) (NN analyst)) (PP (IN with) (NP (organization (NNP Prudential) (NNP Bache))))) (, ,)) (VP (VBD said) (SBAR (IN that) (S (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN growth)))) (VP (MD will) (`` `) (VP (`` `) (VP (VB look) (ADJP (RB especially) (JJ good) (PP (IN as) (PP (VBN compared) (PP (TO to) (NP (JJ other) (NNS companies)))))) (SBAR (IN if) (S (NP (DT the) (NN economy)) (VP (VBZ turns) (ADVP (RB downward))))))))))) (. .)) )
(TOP (S ('' ') ('' ') (NP (NNP Mr.) (NNP Sweig)) (VP (VBD estimated) (SBAR (IN that) (S (NP (NP (NP (organization (NNP Merck)) (POS 's)) (NN profit)) (PP (IN for) (NP (DT the) (NN quarter)))) (VP (VBD rose) (PP (IN by) (NP (percentage (QP (RB about) (CD 22)) (NN %)))) (, ,) (S (VP (VBN propelled) (PP (IN by) (NP (NP (NNS sales)) (PP (IN of) (NP (NP (PRP$ its) (NN line-up)) (PP (IN of) (NP (NP (JJ fast-growing) (NN prescription) (NNS drugs)) (, ,) (PP (VBG including) (NP (NP (PRP$ its) (JJ anti-cholesterol) (NN drug)) (, ,) (NP (NP (NNP Mevacor)) (: ;) (NP (NP (DT a) (JJ high) (NN blood) (NN pressure) (NN medicine)) (, ,) (NP (NNP Vasotec))) (: ;) (NP (NP (NNP Primaxin)) (, ,) (NP (DT an) (JJ antibiotic)) (, ,)) (CC and) (NP (NP (NNP Pepcid)) (, ,) (NP (DT an) (NN anti-ulcer) (NN medication)))))))))))))))))) (. .)) )
(TOP (S (S (NP (NN Profit)) (VP (VBD climbed) (SBAR (RB even) (IN though) (S (NP (NP (organization (NNP Merck)) (POS 's)) (NNS sales)) (VP (AUX were) (VP (VBN reduced) (PP (IN by) (NP (`` `) (NP (`` `) (NP (QP (CD one) (TO to) (CD three)) (NN percentage) (NNS points)) ('' ')) ('' ') (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (DT the) (JJ strong) (NN dollar))))))))))))) (, ,) (NP (NNP Mr.) (NNP Sweig)) (VP (VBD said)) (. .)) )
(TOP (S (PP (IN In) (NP (date (NP (DT the) (JJ third) (NN quarter)) (PP (IN of) (NP (CD 1988)))))) (, ,) (NP (organization (NNP Merck))) (VP (VBD earned) (NP (NP (QP (money ($ $) (CD 311.8) (CD million)))) (, ,) (CC or) (NP (NP (money (CD 79) (NNS cents))) (NP (DT a) (NN share))))) (. .)) )
(TOP (S (PP (IN In) (NP (NP (NNP Rahway)) (, ,) (NP (NNP N.J.)))) (, ,) (NP (DT a) (organization (NNP Merck)) (NN spokesman)) (VP (VBD said) (SBAR (S (NP (DT the) (NN company)) (VP (AUX does) (RB n't) (VP (VB make) (NP (NNS earnings) (NNS projections))))))) (. .)) )
(TOP (S (NP (NNP Mr.) (NNP Sweig)) (VP (VBD said) (SBAR (S (NP (PRP he)) (VP (VBD estimated) (SBAR (IN that) (S (NP (NP (NP (person (NNP Lilly)) (POS 's)) (NNS earnings)) (PP (IN for) (NP (DT the) (NN quarter)))) (VP (VBD jumped) (NP (percentage (QP (RB about) (CD 20)) (NN %))) (, ,) (PP (ADVP (RB largely)) (IN because) (IN of) (NP (NP (DT the) (NN performance)) (PP (IN of) (NP (PRP$ its) (JJ new) (NN anti-depressant) (NNP Prozac)))))))))))) (. .)) )
(TOP (S (NP (NP (DT The) (NN drug)) (, ,) (VP (VBN introduced) (NP (date (JJ last) (NN year)))) (, ,)) (VP (AUX is) (VP (VBN expected) (S (VP (TO to) (VP (VB generate) (NP (NP (NNS sales)) (PP (IN of) (NP (QP (RB about) (money ($ $) (CD 300) (CD million)))))) (NP (date (DT this) (NN year)))))))) (. .)) )
(TOP (S (`` `) (S (`` `) (NP (PRP It)) (VP (AUX 's) (VP (VBG turning) (PRT (RP out)) (S (VP (TO to) (VP (AUX be) (NP (DT a) (JJ real) (NN blockbuster)))))))) (, ,) ('' ') ('' ') (NP (NNP Mr.) (NNP Sweig)) (VP (VBD said)) (. .)) )
(TOP (S (PP (IN In) (NP (NP (date (JJ last) (NN year)) (POS 's)) (date (JJ third) (NN quarter)))) (, ,) (NP (person (NNP Lilly))) (VP (VBD earned) (NP (NP (QP (money ($ $) (CD 171.4) (CD million)))) (, ,) (CC or) (NP (NP (money ($ $) (CD 1.20))) (NP (DT a) (NN share))))) (. .)) )
(TOP (S (PP (IN In) (NP (location (NNP Indianapolis)))) (, ,) (NP (person (NNP Lilly))) (VP (VBD declined) (NP (NN comment))) (. .)) )
(TOP (S (NP (JJ Several) (NNS analysts)) (VP (VBD said) (SBAR (S (NP (PRP they)) (VP (VBD expected) (S (S (NP (NP (NNP Warner-Lambert) (POS 's)) (NN profit)) (ADVP (RB also)) (VP (TO to) (VP (VB increase) (PP (IN by) (NP (percentage (QP (JJR more) (IN than) (CD 20)) (NN %)))) (PP (IN from) (NP (NP (QP (money ($ $) (CD 87.7) (CD million)))) (, ,) (CC or) (NP (NP (money ($ $) (CD 1.25))) (NP (DT a) (NN share)))))))) (, ,) (S (NP (PRP it)) (VP (VBD reported) (PP (IN in) (NP (NP (DT the) (JJ like) (NN period)) (NP (date (JJ last) (NN year)))))))))))) (. .)) )
(TOP (S (NP (DT The) (NN company)) (VP (AUX is) (VP (VBN praised) (PP (IN by) (NP (NNS analysts))) (PP (IN for) (S (VP (VP (ADVP (RB sharply)) (VBG lowering) (NP (PRP$ its) (NNS costs)) (PP (IN in) (NP (JJ recent) (NNS years)))) (CC and) (VP (VBG shedding) (NP (NP (JJ numerous) (NNS companies)) (PP (IN with) (NP (JJ low) (NN profit) (NNS margins)))))))))) (. .)) )
(TOP (S (NP (NP (DT The) (NN company) (POS 's)) (JJ lean) (NN operation)) (PRN (, ,) (S (NP (NNS analysts)) (VP (VBD said))) (, ,)) (VP (VBD allowed) (S (NP (NP (JJ sharp-rising) (NNS sales)) (PP (IN from) (NP (NP (PRP$ its) (NN cholesterol) (NN drug)) (, ,) (NP (NNP Lopid)) (, ,)))) (VP (TO to) (VP (NN power) (NP (NNS earnings) (NN growth)))))) (. .)) )
(TOP (S (NP (NNP Lopid) (NNS sales)) (VP (AUX are) (VP (VBN expected) (S (VP (TO to) (VP (AUX be) (NP (QP (RB about) (money ($ $) (CD 300) (CD million)))) (NP (date (DT this) (NN year))) (, ,) (ADVP (IN up) (PP (IN from) (NP (QP (money ($ $) (CD 190) (CD million)))) (PP (IN in) (NP (date (CD 1988))))))))))) (. .)) )
(TOP (S (PP (IN In) (NP (NP (NNP Morris) (NNP Plains)) (, ,) (NP (NNP N.J.)))) (, ,) (NP (NP (DT a) (NN spokesman)) (PP (IN for) (NP (DT the) (NN company)))) (VP (VBD said) (SBAR (S (NP (NP (DT the) (NNS analysts) (POS ')) (NNS projections)) (VP (AUX are) (`` `) (`` `) (PP (IN in) (NP (DT the) (NN ballpark))))))) (. .)) )
(TOP (S ('' ') ('' ') (NP (NP (NP (NNP Squibb) (POS 's)) (NN profit)) (, ,) (VP (VBN estimated) (PP (IN by) (NP (NNS analysts))) (S (VP (TO to) (VP (AUX be) (PP (NP (QP (RB about) (CD 18)) (NN %)) (IN above) (NP (NP (QP (DT the) (money ($ $) (CD 123) (CD million)))) (, ,) (CC or) (NP (NP (money ($ $) (CD 1.25))) (NP (DT a) (NN share))))) (, ,) (S (NP (PRP it)) (VP (VBN earned) (PP (IN in) (NP (date (NP (DT the) (JJ third) (NN quarter)) (PP (IN of) (NP (CD 1988)))))))))))) (, ,)) (VP (AUX was) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (RB especially) (JJ strong) (NNS sales)) (PP (IN of) (NP (NP (PRP$ its) (JJ Capoten) (NN drug)) (PP (IN for) (S (VP (VBG treating) (NP (NP (JJ high) (NN blood) (NN pressure)) (CC and) (NP (JJ other) (NN heart) (NN disease)))))))))))) (. .)) )
(TOP (S (NP (DT The) (NN company)) (VP (AUX was) (ADVP (RB officially)) (VP (VBN merged) (PP (IN with) (NP (NNP Bristol-Myers) (NNP Co.))) (NP (date (RBR earlier) (DT this) (NN month))))) (. .)) )
(TOP (S (NP (NNP Bristol-Myers)) (VP (VBD declined) (S (VP (TO to) (VP (VB comment))))) (. .)) )
(TOP (S (NP (NP (NNP Mr.) (NNP Riccardo)) (PP (IN of) (NP (organization (NNP Bear) (NNP Stearns))))) (VP (VBD said) (SBAR (IN that) (S (NP (NP (NP (NP (NNP Schering-Plough) (NNP Corp.) (POS 's)) (VBN expected) (NN profit) (NN rise)) (PP (IN of) (NP (QP (RB about) (percentage (CD 18) (NN %) (TO to) (CD 20) (NN %)))))) (, ,) (CC and) (NP (NP (NP (NNP Bristol-Meyers) (POS 's)) (VBN expected) (NN profit) (NN increase)) (PP (IN of) (NP (percentage (QP (RB about) (CD 13)) (NN %)))))) (VP (AUX are) (ADVP (RB largely)) (SBAR (IN because) (`` `) (`` `) (S (NP (DT those) (NNS companies)) (VP (AUX are) (ADVP (RB really)) (VP (VBN managed) (ADVP (RB well)))))))))) (. .)) )
(TOP (S ('' ') ('' ') (NP (NNP ScheringPlough)) (VP (VBD earned) (NP (NP (QP (money ($ $) (CD 94.4) (CD million)))) (, ,) (CC or) (NP (NP (money (CD 84) (NNS cents))) (NP (DT a) (NN share)))) (, ,) (SBAR (IN while) (S (NP (NNP Bristol-Myers)) (VP (VBD earned) (NP (NP (QP (money ($ $) (CD 232.3) (CD million)))) (, ,) (CC or) (NP (NP (money (CD 81) (NNS cents))) (NP (DT a) (NN share))) (, ,)) (PP (IN in) (NP (NP (DT the) (JJ like) (NN period)) (ADVP (date (NP (DT a) (NN year)) (RBR earlier))))))))) (. .)) )
(TOP (S (PP (IN In) (NP (NP (location (NNP Madison))) (, ,) (NP (NNP N.J.)))) (, ,) (NP (NP (DT a) (NN spokesman)) (PP (IN for) (NP (NNP Schering-Plough)))) (VP (VBD said) (SBAR (S (NP (DT the) (NN company)) (VP (AUX has) (NP (`` `) (NP (`` `) (NP (DT no) (NNS problems)) ('' ')) ('' ') (PP (IN with) (NP (NP (DT the) (JJ average) (NN estimate)) (PP (IN by) (NP (NP (DT a) (NNS analysts)) (SBAR (WHNP (WDT that)) (S (NP (NP (JJ third-quarter) (NNS earnings)) (PP (IN per) (NP (NN share)))) (VP (VBD rose) (PP (IN by) (NP (percentage (QP (RB about) (CD 19)) (NN %)))) (, ,) (PP (TO to) (NP ($ $) (CD 1))))))))))))))) (. .)) )
(TOP (S (S (NP (DT The) (NN company)) (VP (VBZ expects) (S (VP (TO to) (VP (VB achieve) (NP (NP (DT the) (ADJP (percentage (CD 20) (NN %))) (NN increase)) (PP (IN in) (NP (NP (JJ full-year) (NNS earnings)) (PP (IN per) (NP (NN share))))))))) (, ,) (SBAR (IN as) (S (NP (PRP it)) (VP (VBD projected) (PP (IN in) (NP (DT the) (date (NN spring))))))))) (, ,) (NP (DT the) (NN spokesman)) (VP (VBD said)) (. .)) )
(TOP (S (ADVP (RB Meanwhile)) (, ,) (NP (NNS analysts)) (VP (VBD said) (SBAR (S (NP (NP (NP (organization (NNP Pfizer)) (POS 's)) (JJ recent) (NN string)) (PP (IN of) (NP (JJ lackluster) (JJ quarterly) (NNS performances)))) (VP (VBD continued) (, ,) (SBAR (IN as) (S (NP (NP (NNS earnings)) (PP (IN in) (NP (DT the) (NN quarter)))) (VP (AUX were) (VP (VBN expected) (S (VP (TO to) (VP (VB decline) (PP (IN by) (NP (percentage (QP (RB about) (CD 5)) (NN %))))))))))))))) (. .)) )
(TOP (S (NP (NP (NNS Sales)) (PP (IN of) (NP (NP (NP (organization (NNP Pfizer)) (POS 's)) (JJ important) (NNS drugs)) (, ,) (NP (NP (NP (NNP Feldene)) (PP (IN for) (S (VP (VBG treating) (NP (NN arthritis)))))) (, ,) (CC and) (NP (NP (NNP Procardia)) (, ,) (NP (DT a) (NN heart) (NN medicine)) (, ,)))))) (VP (AUX have) (VP (VBN shrunk) (PP (IN because) (IN of) (NP (JJ increased) (NN competition))))) (. .)) )
(TOP (S (`` `) (S (NP (`` `) (DT The) (PRN (-LRB- -LRB-) (JJ strong) (-RRB- -RRB-)) (NN dollar)) (VP (VBD hurt) (NP (NNP Pfizer)) (NP (DT a) (NN lot)) (, ,) (ADVP (RB too)))) (, ,) ('' ') ('' ') (NP (NNP Mr.) (NNP Sweig)) (VP (VBD said)) (. .)) )
(TOP (S (PP (IN In) (NP (DT the) (JJ third) (NN quarter))) (NP (JJ last) (NN year)) (, ,) (NP (NNP Pfizer)) (VP (VBD earned) (NP (NP (QP (money ($ $) (CD 216.8) (CD million)))) (, ,) (CC or) (NP (NP (money ($ $) (CD 1.29))) (NP (DT a) (NN share))))) (. .)) )
(TOP (S (PP (IN In) (NP (location (NNP New) (NNP York)))) (, ,) (NP (DT the) (NN company)) (VP (VBD declined) (NP (NN comment))) (. .)) )
(TOP (S (NP (NNS Analysts)) (VP (VBD said) (SBAR (S (NP (PRP they)) (VP (VBD expected) (S (NP (NP (organization (NNP Upjohn)) (POS 's)) (NN profit)) (VP (TO to) (VP (VP (AUX be) (ADJP (JJ flat))) (CC or) (VP (VB rise) (PP (IN by) (NP (QP (RB only) (IN about) (percentage (CD 2) (NN %) (TO to) (CD 4) (NN %))))) (SBAR (IN as) (S (PP (VBN compared) (PP (IN with) (NP (NP (QP (money ($ $) (CD 89.6) (CD million)))) (, ,) (CC or) (NP (NP (money (CD 49) (NNS cents))) (NP (DT a) (NN share)))))) (, ,) (NP (PRP it)) (VP (VBD earned) (ADVP (NP (DT a) (NN year)) (RB ago))))))))))))) (. .)) )
(TOP (S (NP (NP (organization (NNP Upjohn)) (POS 's)) (JJ biggest-selling) (NNS drugs)) (VP (AUX are) (NP (NP (NP (NNP Xanax)) (, ,) (NP (DT a) (NN tranquilizer))) (, ,) (CC and) (NP (NP (NNP Halcion)) (, ,) (NP (DT a) (NN sedative))))) (. .)) )
(TOP (S (NP (NP (NNS Sales)) (PP (IN of) (NP (DT both) (NNS drugs)))) (VP (AUX have) (VP (AUX been) (VP (VBN hurt) (PP (IN by) (NP (NP (JJ new) (NN state) (NNS laws)) (VP (VBG restricting) (NP (NP (DT the) (NNS prescriptions)) (PP (IN of) (NP (NP (JJ certain) (NN tranquilizing) (NNS medicines)) (CC and) (NP (NP (JJ adverse) (NN publicity)) (PP (IN about) (NP (NP (DT the) (JJ excessive) (NN use)) (PP (IN of) (NP (DT the) (NNS drugs))))))))))))))) (. .)) )
(TOP (S (S (S (ADVP (RB Also)) (, ,) (NP (NP (NP (DT the) (NN company) (POS 's)) (JJ hair-growing) (NN drug)) (, ,) (NP (NNP Rogaine)) (, ,)) (VP (AUX is) (VP (VBG selling) (ADVP (RB well)) (: --) (PP (IN at) (NP (NP (QP (RB about) (money ($ $) (CD 125) (CD million)))) (PP (IN for) (NP (DT the) (NN year)))))))) (, ,) (CC but) (S (NP (NP (NP (DT the) (NN company) (POS 's)) (NN profit)) (PP (IN from) (NP (DT the) (NN drug)))) (VP (AUX has) (VP (AUX been) (VP (VBN reduced) (PP (IN by) (NP (NP (organization (NNP Upjohn)) (POS 's)) (JJ expensive) (NN print) (CC and) (NN television) (NNS campaigns))) (PP (IN for) (NP (NN advertising)))))))) (, ,) (NP (NNS analysts)) (VP (VBD said)) (. .)) )
(TOP (S (PP (IN In) (NP (NP (NNP Kalamazoo)) (, ,) (NP (NNP Mich.)))) (, ,) (NP (organization (NNP Upjohn))) (VP (VBD declined) (NP (NN comment))) (. .)) )
